Infant Formula
Latest news and updates related to infant formula
About Infant Formula coverage
The Infant Formula news hub on Global Investing News tracks 2 recent headlines that matter to investors, policy watchers, and market strategists. Use this page to monitor how Infant Formula developments affect earnings expectations, sector rotation, supply chains, regulation, and cross-asset volatility. Stories are grouped by source type — market data, company announcements, regulatory filings, and expert analysis — so you can scan the signal quickly without wading through duplicate wire copy. When a headline links to a full article, you will find expanded context, key facts, and prediction-market angles where available. Bookmark this hub if you follow Infant Formula across quarters; new items are added as our crawl pipeline ingests fresh sources throughout the trading day.
Explore related topics
Latest Infant Formula headlines
Market Data
(2)China’s Low Birthrate Isn’t Doomsday for Formula Milk Suppliers
While China's plummeting birthrate—which hit a record low in 2023—presents a structural headwind for the infant nutrition sector, the narrative of 'industry doomsday' is increasingly challenged by 'premiumization' and market consolidation. Investors should note that while the volume of prospective customers is shrinking, the average revenue per user (ARPU) is rising as Chinese parents pivot toward high-end, scientifically fortified, and specialty formulas. This shift favors deep-pocketed incumbents like China Feihe and multinational giants like Nestlé and Danone, who can afford the R&D required to meet stringent new national safety standards (GB standards) implemented in 2023. These regulations have effectively flushed out smaller, low-tier competitors, allowing dominant players to grab market share even in a stagnant market. Furthermore, suppliers are diversifying into 'adult nutrition' and 'silver economy' products to hedge against demographic declines. Moving forward, the key metrics for investors will be operating margins and inventory turnover rather than simple volume growth. Watch for further M&A activity as the industry stabilizes around a few 'national champions' and high-tech foreign explorers.
Abbott Stock Slumps. The Nutrition Business Is a Drag on Earnings.
Abbott Laboratories (ABT) is facing significant headwinds as its pediatric nutrition segment continues to weigh on overall financial performance, overshadowing gains in its medical device and diagnostics divisions. This slump is primarily rooted in the lingering aftermath of the 2022 infant formula recall and the subsequent closure of its Sturgis facility, which has allowed competitors like Reckitt Benckiser to gain market share. While Abbott has restored much of its production capacity, the recovery of consumer trust and shelf space remains a slow, capital-intensive process. From a broader sector perspective, this highlights a divergence within the healthcare conglomerate: while the medical device segment thrives—driven by the FreeStyle Libre glucose monitor and recovery in elective surgeries—the nutrition business remains a multi-year recovery story. Investors should view this as a transitionary phase where the high-margin med-tech business is being offset by lower-margin specialty retail recovery. Forward-looking, the key metric for investors will be whether the anticipated double-digit growth in medical devices can accelerate enough to compensate for the stagnation in the nutrition segment, especially as birth rates trend lower in key markets.
Get alerts for this topic
Subscribe to receive updates about "Infant Formula"